NASDAQ:ATRCAtriCure Stock Price, Forecast & News

AtriCure's stock was trading at $35.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATRC shares have increased by 43.5% and is now trading at $50.61. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AtriCure.

AtriCure is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for AtriCure.

AtriCure Inc. (NASDAQ:ATRC) posted its quarterly earnings results on Wednesday, April, 29th. The medical device company reported ($0.42) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.01. The medical device company earned $53.20 million during the quarter, compared to analysts' expectations of $54.13 million. AtriCure had a negative net margin of 19.98% and a negative return on equity of 19.19%. The business's quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.20) EPS. View AtriCure's earnings history.

AtriCure updated its first quarter 2020 Pre-Market earnings guidance on Thursday, April, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $53.2-53.2 million, compared to the consensus revenue estimate of $59.84 million.

9 brokers have issued 1 year target prices for AtriCure's shares. Their forecasts range from $30.00 to $56.00. On average, they anticipate AtriCure's stock price to reach $46.22 in the next twelve months. This suggests that the stock has a possible downside of 8.7%. View analysts' price targets for AtriCure.

Media headlines about ATRC stock have trended extremely positive recently, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AtriCure earned a news impact score of 4.3 on InfoTrie's scale. They also assigned press coverage about the medical device company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutAtriCure.

Some companies that are related to AtriCure include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Amgen (AMGN), Gilead Sciences (GILD), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), Allergan (AGN), CVS Health (CVS), Walt Disney (DIS) and Intel (INTC).

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

AtriCure's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.75%), Wellington Management Group LLP (5.06%), Champlain Investment Partners LLC (4.23%), Invesco Ltd. (3.83%), Fred Alger Management LLC (3.15%) and GW&K Investment Management LLC (2.67%). Company insiders that own AtriCure stock include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves. View institutional ownership trends for AtriCure.

ATRC stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Peregrine Capital Management LLC, BlackRock Inc., GW&K Investment Management LLC, The Manufacturers Life Insurance Company , Paradigm Capital Management Inc. NY, DAFNA Capital Management LLC, and Eagle Asset Management Inc.. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, and Michael H Carrel. View insider buying and selling activity for AtriCure.

ATRC stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Invesco Ltd., Orbimed Advisors LLC, Champlain Investment Partners LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Nuveen Asset Management LLC, and Granahan Investment Management Inc. MA. View insider buying and selling activity for AtriCure.

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ATRC stock can currently be purchased for approximately $50.61.

AtriCure has a market capitalization of $2.03 billion and generates $230.81 million in revenue each year. The medical device company earns $-35,190,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. AtriCure employs 620 workers across the globe.

The official website for AtriCure is www.atricure.com.

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.